Nuchev Limited Overview
Nuchev is a sub-scale, Melbourne-based nutrition and wellness company that began life as a single-brand goat-milk infant formula business (Oli6®) and has, since 2023, been reshaped into a multi-brand "house of brands" and distribution platform. Its three operating engines are: consumer nutrition (Oli6 goat-milk formula and adjacent goat-nutrition foods, ranged nationally in Chemist Warehouse, Coles and Woolworths and sold into China cross-border e-commerce, Vietnam and Cambodia); practitioner health (owned BioPractica and Medicine Tree brands plus licensed European complementary-medicine brands, acquired via the A$7m bWellness deal in 2024); and third-party distribution (Brauer, Skin Physics, Rapid Loss, and from August 2026 the Kuci women's-health range). FY26 revenue was A$25.7m, up 12% and at a 27.5% four-year CAGR, but the business remains loss-making (adjusted EBITDA loss A$4.6m), cash-constrained (A$2.1m closing cash) and strategically and financially dependent on its largest shareholder, H&S Group.
Company's own description (latest disclosures)
In its FY26 Full Year Results release (27 Aug 2026), Nuchev describes itself as an Australian nutrition, wellness and health-products business whose portfolio includes the owned brands Oli6®, BioPractica and Medicine Tree, alongside health and wellness products distributed or sold under exclusive licence in Australia and New Zealand. It states that products reach consumers through grocery, pharmacy, practitioner, digital and selected international channels, that Oli6 is sold through major Australian grocery and pharmacy channels and in China cross-border e-commerce (CBEC), Vietnam and Cambodia, and that Nuchev distributes Brauer, Skin Physics and Rapid Loss products in Australia. The corporate tagline is "Inspiring healthier, happier futures for all." The Half Year presentation (Feb 2026) framed the purpose as building nutrition brands that families can rely on from early life onward, under a "House of Brands" strategy.
The FY26 Results Presentation organises the business as "one integrated nutrition and wellness business" across three platforms — Consumer nutrition (Oli6), Practitioner health (BioPractica, Medicine Tree) and Distribution (Brauer, Skin Physics, Rapid Loss) — served through six routes to market: grocery, pharmacy, practitioner, digital/DTC, China CBEC and Vietnam.
Independent characterisation
Nuchev is best understood as an asset-light brand owner and distributor rather than a manufacturer. It does not own production facilities: Oli6 has historically been blended and canned by third-party Australian manufacturers (a 2017 partnership with CNCA-certified Nature One Dairy in Melbourne), using goat milk imported from the Netherlands (per IPO-era disclosures). Practitioner products are sourced from owned-brand contract manufacturing and European licensors; distributed brands are sourced from H&S-affiliated brand owners.
The company has gone through three distinct business-model eras:
-
2013–2022: single-brand China-oriented goat formula. The IPO thesis (Dec 2019) was premium goat infant formula for Australia and, critically, China, where the company sold via CBEC (Tmall, JD, VIP) and daigou while pursuing SAMR registration for offline sales. Revenue peaked around FY20 and fell sharply in FY21–FY23.
-
2023–2025: reset and diversification under H&S sponsorship. Following a strategic review, China/Vietnam distribution was outsourced exclusively to H&S Group (from July 2023), which also became a cornerstone shareholder. In 2024 Nuchev acquired bWellness (practitioner/complementary medicines), roughly doubling revenue in FY25.
-
2025–present: multi-engine nutrition and wellness platform. Under CEO Nathan Cheong (ex-Melrose, LifeSpace, BioCeuticals), Nuchev added third-party distribution (Brauer and others, first as agent in May 2025, then as full distributor from March 2026), launched Oli6 adjacencies, and in August 2026 signed a consignment deal for Kuci women's-health probiotics.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue type | Almost entirely product revenue (wholesale sales to retailers, distributors, practitioners and CBEC partners); small DTC/e-commerce component; agency commission income during May 2025–Mar 2026 for Brauer/Skin Physics/Rapid Loss, replaced by gross distribution sales from March 2026; consignment margin model for Kuci from Aug 2026 |
| Service / subscription / licensing | None material (Nuchev is a licensee of European brands, not a licensor) |
| Value-chain position | Brand ownership, product development, regulatory registration, marketing, key-account management and distribution; manufacturing outsourced |
| Customer types | Major retailers (Chemist Warehouse, Coles, Woolworths); international distributors (H&S for China/Vietnam); CBEC platforms; naturopaths/clinicians, natural-medicine practices, pharmacies and health-food stores (practitioner); consumers via Oli6Goat.com and BioPractica B2B ecommerce |
| End markets | Infant and toddler formula; goat-milk adult/family nutrition and functional foods; children's snacks; complementary medicines/nutraceuticals; homeopathics; skincare; weight management; women's health probiotics |
| Geography | ANZ 76% of FY26 revenue; International 24% (China A$4.9m, Vietnam A$1.4m) |
Strategy
Stated strategy (themes, FY26 Results Presentation and release)
Management's FY26 framing is a pivot from growth to conversion, margin and cash. The five strategic priorities, in management's own short labels, are: (1) Strengthen Oli6; (2) Rebuild Practitioner; (3) Scale distribution; (4) Commercialise innovation; and (5) Convert growth. These are mapped onto "four growth engines" — the Oli6 platform, the Practitioner platform, the Distribution platform, and Innovation plus digital — intended to reduce reliance on any one product, geography or channel. The core economic argument is that Nuchev has already built people, systems, supply-chain, regulatory and route-to-market capability for a larger business, so incremental revenue should flow through without proportional growth in fixed costs. The CEO characterised FY27 as getting more from what is already in place rather than reinventing the business.
The Half Year (Feb 2026) materials articulated a "House of Brands" strategy with priorities around revenue quality, disciplined portfolio management, and long-term brand strength supported by responsible capital management.
Strategic initiatives in the last 24 months
| Date | Initiative | Type | Status / outcome |
|---|---|---|---|
| May 2024 – FY25 | bWellness integration (BioPractica, Medicine Tree, licensed European brands) | Acquisition / diversification | Revenue contribution delivered in FY25; Practitioner softened in 2H FY26; goodwill fully impaired (A$1.873m) |
| FY25 | Oli6 launch in Vietnam (via H&S) | Market entry | Contributed early; FY26 Vietnam revenue A$1.4m; new-product registrations on hold |
| 1 May 2025 | Exclusive sales agency for Brauer / H&S Brand Corporation products | New business line | Converted to distribution in March 2026 |
| May 2025 | CEO transition to Nathan Cheong | Leadership | Executed |
| FY26 | Oli6 adjacencies: children's snacking, Nighty Night Goat, updated Full Cream Goat Milk Powder | Product innovation | Launched |
| FY26 | BioPractica practitioner e-commerce platform | Digital | Live |
| 4 Mar 2026 | Transition to full distribution model for Brauer, Skin Physics, Rapid Loss | Business-model change | Implemented; FY27 is first full year |
| 15 May 2026 | A$4m shareholder working-capital facility (expanded to A$6.0m total facilities by 30 Jun 2026) | Funding | A$3.5m drawn at year end; maturity 31 Mar 2028 |
| Jun 2026 | Oli6Goat.com launch | Digital / D2C | Live |
| 28 Aug 2026 | Kuci women's health exclusive distribution (consignment) via Chemist Warehouse | New category | Rollout commencing; no minimum commitments |
| Sep 2026 | Enforcement of Nouvlait arbitration award | Legal recovery | Enforcement through PRC courts being initiated |
Cost programmes and ESG commitments
No formal quantified cost-reduction programme has been announced for FY27. Management has listed downside levers: reducing/deferring discretionary expenditure, managing purchasing and inventory, adjusting launch timing, focusing on debtor collections and sequencing supplier payments. No quantified sustainability or ESG commitments were identified.
Medium-term targets and guidance
No formal FY27 earnings guidance or medium-term financial targets have been provided. FY27 planning assumptions (explicitly not guidance): continued growth in domestic retail; full-year contribution from the Brauer distribution portfolio; progress in international markets; a rebuilding of Practitioner; and further drawdown within existing facilities as required. Earlier (2024), the Chair framed capital raising as a step toward a break-even cash position; this has not yet been achieved.
Products & Services
Pricing models are not disclosed for any product; all products are sold at wholesale to retailers/distributors with recommended retail prices set in market. Launch years are given where disclosed.
Consumer nutrition — Oli6®
| Product / line | Description and key attributes | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Oli6 Goat Milk Infant Formula (Stage 1) | Goat-milk-based infant formula positioned on digestion, gentleness and immunity | Parents of infants 0–6 months | Brand launched 2016; Stage 1 relaunch referenced in FY25 presentation materials | Core of Australian pharmacy/grocery ranging |
| Oli6 Follow-on Formula (Stage 2) | Goat-milk follow-on formula | Infants 6–12 months | Since 2016 | — |
| Oli6 Toddler Milk Drink (Stage 3) | Goat-milk toddler drink; voted ProductReview No.1 toddler milk in 2021, 2022 and 2023 | Toddlers 1–3 years | Since 2016 | Flagship awards claim |
| Oli6 Stage 4 | Junior/children's goat-milk formula | Children 3+ | Launch referenced in FY25 presentation | — |
| Oli6 Premium range | Reformulated premium goat infant formula range; company described it as a first-of-kind goat formulation | Premium-seeking parents (Australia/China) | 2,021 | — |
| Oli6 Full Cream Goat Milk Powder / Adult Milk Powder | Goat milk powder for family/adult nutrition; updated formats in FY26 | Adults, families | Adult powder pre-IPO; updated formats FY26 | Adjacent category |
| Oli6 Nighty Night Goat | Functional goat-nutrition food product (evening/sleep-routine positioning) | Children/families | FY26 | New adjacency |
| Oli6 children's snacking range | Goat-milk-based children's snacks | Children | FY26 | New adjacency |
| Oli6 bovine-milk product | Cow's-milk-based nutrition product under Oli6 | Parents | Referenced 2024 | Details not publicly disclosed |
| Oli6Goat.com | Dedicated D2C/brand website for non-infant-formula Oli6 range | Consumers | Live June 2026 | Digital channel |
Practitioner health
| Product / brand | Description | Target customer | Ownership | Notes |
|---|---|---|---|---|
| BioPractica | Practitioner nutraceuticals range | Naturopaths, clinicians, practitioner pharmacies | Owned (via bWellness, 2024) | Gained traction in FY26; new practitioner e-commerce platform |
| Medicine Tree (Therapeutics) | Practitioner complementary medicines, manufactured in Australia by Brauer Professional (per 2024 reporting) | Practitioners | Owned (via bWellness) | — |
| Heel | German homeopathic/biological medicine brand | Practitioners, pharmacies | Licensed/distributed in ANZ | — |
| Dr. Reckeweg | German homeopathic brand | Practitioners | Licensed/distributed | Imported per 2024 reporting |
| Magnesium Diasporal | Magnesium supplement range (Protina) | Practitioners, pharmacies | Licensed/distributed | — |
| Basica | Alkaline mineral supplement range (Protina) | Practitioners, pharmacies | Licensed/distributed | — |
| BioGaia | Probiotic brand | Practitioners/pharmacy | Represented in ANZ (company profile) | Current status not re-verified for FY26 |
| Froximun | European health products brand | Practitioners | Represented in ANZ (company profile) | Current status not re-verified |
| BioPractica practitioner e-commerce site | B2B ordering platform for clinicians, practices, pharmacies and health-food retailers covering BioPractica, Magnesium Diasporal, Basica, Medicine Tree and Heel | Trade customers | Launched FY26 | — |
At acquisition (May 2024), bWellness distributed around 200 products, with vitamins and dietary supplements generating most revenue, followed by sports products and exports.
Distribution portfolio
| Brand | Category | Arrangement | Since | Notes |
|---|---|---|---|---|
| Brauer | Natural medicine / wellness (practitioner and retail heritage brand) | Exclusive agency (May 2025) → full distribution (4 Mar 2026) with H&S Global (Au) | 2,025 | Contribution rose late FY26 as supply improved |
| Skin Physics | Science-led skincare / beauty | As above | 2025/2026 | — |
| Rapid Loss (also referred to as "Rapid") | Weight management / performance nutrition | As above | 2025/2026 | — |
| Kuci | Women's health probiotics, clinically researched strains, life-stage positioning | Exclusive distribution on consignment from related-party Biomera Biotics; exclusive national rollout through Chemist Warehouse; Nuchev earns margin on sell-through; no minimum purchase commitments | Aug 2026 | Capital-light model |
Financial Narrative
The five fiscal years analysed are FY22–FY26. FY26 figures are from the audited FY26 accounts (via ASX release/presentation and S&P Global); FY22–FY25 figures are from S&P Global Market Intelligence (via StockAnalysis), cross-checked against company releases where available.
Income statement
Notes: Operating loss for FY25–FY26 is company-reported (FY26 presentation scorecard); S&P Global shows FY25 operating loss of A$4.35m (difference due to classification of other income/unusual items). FY23–FY25 EPS per InvestSMART; FY22 and FY26 EPS are analyst-derived (FY22 on year-end shares of 51.77m with no issuance during the year; FY26 on an estimated weighted average of ~151m shares) and should be checked against the Appendix 4E. Diluted EPS equals basic because potential shares are anti-dilutive in loss years. The company has never paid a dividend.
Margin profile
Revenue CAGR FY22–FY26: 27.5% (company-stated and confirmed by calculation: 25.68 / 9.72 = 2.64x over four years).
Balance sheet
Notes: FY26 long-term debt comprises A$3.5m drawn under the H&S facilities plus A$0.48m of lease liabilities. The company reported FY26 net current assets of A$7.6m (vs S&P Global working capital of A$7.48m — minor classification difference) and net assets of A$5.9m. The FY24 goodwill of A$4.22m arose on the bWellness acquisition; in FY25 the purchase-price allocation split this into A$1.87m goodwill and A$2.34m other intangibles (customer/brand assets); the residual goodwill was fully impaired at 30 June 2026.
Cash flow
FY26 company cash bridge: opening cash A$3.607m; operating outflow A$6.639m; investing outflow A$0.083m; financing inflow A$5.267m (A$1.926m share proceeds, A$3.500m borrowings, less leases); FX -A$0.026m; closing cash A$2.125m.
Ratios
All ratios analyst-calculated from the tables above. Net debt/EBITDA and interest coverage are not meaningful because EBITDA and EBIT are negative in every year. ROIC proxy uses company operating loss for FY25 (-4.0) and FY26 (-7.2).
Commentary on trends, inflections and drivers
Revenue. The five-year series shows a clear U-shape: revenue contracted in FY22 and FY23 (to A$8.8m) as the original China-centric model unwound, then recovered in FY24 (+29%) on the back of the H&S China/Vietnam distribution agreement and stronger domestic ranging, before doubling in FY25 (+102%) principally because of the bWellness acquisition (practitioner revenue) and continued Oli6 growth. FY26 growth slowed to 12%, with the composition shifting sharply: ANZ revenue rose 37.9% to A$19.4m while International fell 29.3% to A$6.3m. Domestic growth in FY26 was driven by Oli6 in Chemist Warehouse, Coles and Woolworths and by distribution revenue from Brauer after March 2026; international weakness reflected distributor ordering and shipment timing, China CBEC event timing and, in Vietnam, a pause in new-product registrations under a revised regulatory framework. The Q4 FY26 quarterly reported "group sales revenue" of A$24.1m against statutory revenue of A$25.7m — the gap likely reflects definitional differences between sales revenue in the 4C and statutory revenue (which may include other income lines or gross-up of distribution sales); investors should rely on the audited A$25.7m.
Gross margin. Gross margin was structurally poor in FY22–FY24 (22–32%), consistent with inventory provisions, discounting and sub-scale procurement during the China reset (inventory fell from A$9.6m in FY22 to A$5.2m in FY24, a A$6.4m liquidation). The FY25 step-up to 47.3% reflected the higher-margin practitioner portfolio and better Oli6 mix. FY26 margin fell 3.7pp to 43.6% as cost of sales rose 19.9% against 12.0% revenue growth; the company attributes this to channel and product mix, promotional activity, product costs and logistics, and the growing share of distribution revenue (which carries lower gross margins than owned brands). The derived 2H FY26 margin of ~41% suggests the mix headwind intensified after the March distribution transition.
Operating costs and EBITDA. Adjusted EBITDA losses narrowed consistently from -A$10.2m (FY22) to -A$3.3m (FY25) — a A$6.9m improvement driven by cost reduction and the gross-profit uplift from bWellness. FY26 reversed this, with the loss widening 36.3% to -A$4.6m because gross profit grew only A$0.3m while employee costs rose A$1.3m (+20.8%) and sales and marketing A$0.3m (+6.2%), reflecting investment in people, new products, digital capability and the distribution business ahead of revenue.
Statutory loss. FY26 net loss of A$7.4m (+93%) comprised the adjusted EBITDA loss (A$4.6m), D&A and inventory provisions (A$0.8m), the full goodwill impairment on Practitioner (A$1.9m) and net finance costs (A$0.2m). The impairment, while non-cash, is an important signal: it means management could not support with evidence at balance date the cash-flow forecasts underpinning the bWellness acquisition goodwill only two years after the deal.
Balance sheet. The balance sheet has moved from heavily net-cash and inventory-rich (FY22) to thin and levered (FY26). Equity has fallen from A$15.8m to A$5.9m; accumulated losses exceed A$109m against A$113m of contributed equity — meaning almost all capital raised since inception, including the ~A$48.6m IPO, has been consumed. FY26 receivables nearly doubled (+96.6%) and payables almost tripled (+185%) with the distribution model; inventory rose 37.3%. Net cash of A$3.2m at FY25 became net debt of A$2.1m at FY26.
Cash flow. Operating cash burn has averaged roughly A$5.1m per year over five years and accelerated to A$6.6m in FY26 because of the working-capital build. The business has required external funding in four of the last four years with burn (FY23 and FY24 equity raises of ~A$6.5m each; FY26 equity of A$1.9m plus A$3.5m debt). With A$2.1m of cash and A$2.5m of undrawn facilities at 30 June 2026, total liquidity of ~A$4.6m covers less than one year at the FY26 burn rate, which is why the auditors' going-concern material uncertainty is disclosed.
Working-capital efficiency. The cash conversion cycle has improved dramatically, from 533 days (FY22) to 99 days (FY26). However, the FY26 improvement was achieved largely by stretching payables to 191 days — a level that is unlikely to be sustainable and may partly reflect amounts owed to related-party brand suppliers — while DSO deteriorated to 82 days and DIO rose to 208 days.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Platform Details
| Platform (as presented FY26) | Contents | Brands / products | Channels | FY26 qualitative performance (company) |
|---|---|---|---|---|
Consumer nutrition | Goat-milk infant, toddler and family nutrition; functional foods; children's snacks | Oli6® Stage formulas, Oli6 Full Cream Goat Milk Powder, Oli6 Nighty Night Goat, Oli6 children's snacking range | Grocery (Coles, Woolworths), pharmacy (Chemist Warehouse), Oli6Goat.com, China CBEC, Vietnam, Cambodia | Domestic Oli6 described as the Group's most consistent contributor; international uneven and below expectations |
Practitioner health | Practitioner-only and pharmacy complementary medicines, nutraceuticals and homeopathics | Owned: BioPractica, Medicine Tree; licensed: Heel, Magnesium Diasporal, Basica (Protina), and per company profile BioGaia, Froximun, Dr. Reckeweg | Clinicians, natural-medicine practices, pharmacies, health-food stores; B2B e-commerce | Stronger early in FY26, then softened (distributor disruption, channel inventory, uneven ordering); full goodwill impaired |
Distribution | Third-party health, wellness and beauty brands | Brauer, Skin Physics, Rapid Loss; Kuci (from Aug 2026, consignment) | Retail, pharmacy, digital | Contribution rose in the closing months of FY26 after the March 2026 shift to distribution |
Revenue by Segment
| Segment / line (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Oli6 Nutritionals revenue (AUD Mn) | 10.9 | 14.9 | — |
Other revenue incl. practitioner, agency and raw-material sales (AUD Mn, derived residual) | 0.4 | 8.0 | — |
Group revenue (AUD Mn) | 11.3 | 22.9 | 25.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | 1H FY2025 | 2H FY2025 | 1H FY2026 | 2H FY2026 |
|---|---|---|---|---|
Revenue (AUD Mn) | 11.0 | 11.9 | 12.4 | 13.3 |
Gross profit (AUD Mn) | — | — | 5.72 | 5.48 |
Gross margin (%) | — | — | 46.2 | 41.2 |
EBITDA (AUD Mn, as reported at half; FY derived) | -1.5 | -1.8 | -2.1 | -2.5 |
Net loss after tax (AUD Mn) | -1.58 | -2.24 | -2.34 | -5.05 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 9.72 | 8.79 | 11.34 | 22.94 | 25.68 |
Revenue growth (%) | -10.8 | -9.6 | 29.0 | 102.2 | 12.0 |
Cost of sales (AUD Mn) | 6.90 | 6.89 | 7.72 | 12.08 | 14.48 |
Gross profit (AUD Mn) | 2.82 | 1.90 | 3.63 | 10.86 | 11.20 |
Employee benefits expense (AUD Mn) | — | — | — | 6.1 | 7.4 |
Sales and marketing expense (AUD Mn) | — | — | — | 4.2 | 4.5 |
Adjusted EBITDA (AUD Mn, company non-IFRS) | -10.2 | -7.4 | -5.9 | -3.3 | -4.6 |
Depreciation and amortisation (AUD Mn) | 0.13 | 0.14 | 0.11 | 0.73 | 0.61 |
Impairments and write-downs (AUD Mn) | 0 | 0.51 | 0 | 0 | 1.87 |
Operating loss (AUD Mn) | -11.09 | -8.23 | -6.58 | -4.0 | -7.2 |
Pre-tax loss (AUD Mn) | -11.11 | -8.81 | -7.32 | -3.82 | -7.39 |
Net loss after tax (AUD Mn) | -11.11 | -8.81 | -7.32 | -3.82 | -7.39 |
EPS basic (AUD cents) | -21.5 | -16.0 | -7.3 | -2.8 | -4.9 |
EPS diluted (AUD cents) | -21.5 | -16.0 | -7.3 | -2.8 | -4.9 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 29.0 | 21.6 | 32.0 | 47.3 | 43.6 |
Adjusted EBITDA margin (%) | -104.9 | -84.2 | -52.0 | -14.4 | -17.9 |
Operating margin (%) | -114.1 | -93.6 | -58.0 | -17.4 | -28.0 |
Net margin (%) | -114.3 | -100.2 | -64.6 | -16.7 | -28.8 |
Balance Sheet and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 17.75 | 15.32 | 20.09 | 17.39 | 19.60 |
Cash and equivalents (AUD Mn) | 5.11 | 7.48 | 7.61 | 3.61 | 2.13 |
Receivables (AUD Mn) | 1.66 | 0.67 | 2.13 | 3.00 | 5.90 |
Inventory (AUD Mn) | 9.62 | 6.20 | 5.18 | 5.54 | 8.26 |
Total current assets (AUD Mn) | 16.66 | 14.60 | 15.22 | 12.40 | 16.60 |
Goodwill (AUD Mn) | 0 | 0 | 4.22 | 1.87 | 0 |
Other intangibles (AUD Mn) | 0.25 | 0 | 0 | 2.34 | 1.99 |
Trade payables (AUD Mn) | 0.67 | 0.70 | 1.60 | 1.80 | 7.59 |
Total current liabilities (AUD Mn) | 1.84 | 2.19 | 4.94 | 5.39 | 9.11 |
Short-term debt incl. current leases (AUD Mn) | 0.15 | 0.05 | 0.09 | 0.12 | 0.21 |
Long-term debt incl. leases (AUD Mn) | 0 | 0.24 | 0.24 | 0.27 | 3.98 |
Total debt (AUD Mn) | 0.15 | 0.28 | 0.32 | 0.39 | 4.19 |
Net debt (AUD Mn; negative = net cash) | -4.97 | -7.21 | -7.29 | -3.21 | 2.07 |
Total liabilities (AUD Mn) | 1.92 | 2.51 | 5.34 | 6.16 | 13.67 |
Shareholders' equity (AUD Mn) | 15.83 | 12.82 | 14.75 | 11.23 | 5.93 |
Working capital (AUD Mn) | 14.83 | 12.41 | 10.28 | 7.00 | 7.48 |
Accumulated losses (AUD Mn) | -82.12 | -90.93 | -98.25 | -102.07 | -109.46 |
Contributed equity (AUD Mn) | 96.04 | 101.86 | 111.06 | 111.04 | 113.23 |
Shares outstanding (M) | 51.77 | 84.41 | 146.34 | 146.34 | 156.82 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -8.30 | -3.26 | -3.73 | -3.74 | -6.64 |
Change in working capital (AUD Mn) | 1.70 | 4.69 | 3.27 | -0.77 | -2.14 |
Capital expenditure (AUD Mn) | -0.01 | -0.06 | -0.01 | -0.18 | -0.02 |
Free cash flow (AUD Mn) | -8.31 | -3.32 | -3.74 | -3.93 | -6.66 |
Acquisitions, net of cash (AUD Mn) | 0 | 0 | -2.18 | 0.08 | 0 |
Equity issued (AUD Mn) | 0 | 6.53 | 6.51 | 0 | 1.93 |
Borrowings drawn (AUD Mn) | 0 | 0 | 0 | 0 | 3.50 |
Lease repayments (AUD Mn) | -0.12 | -0.15 | -0.09 | -0.10 | -0.16 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD Mn) | -9.40 | 2.37 | 0.13 | -4.00 | -1.48 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on year-end equity (%) | -70.2 | -68.7 | -49.6 | -34.0 | -124.6 |
ROA on year-end assets (%) | -62.6 | -57.5 | -36.4 | -22.0 | -37.7 |
ROIC proxy: EBIT / (equity + debt) (%) | -69.4 | -62.8 | -43.7 | -34.4 | -71.1 |
Current ratio (x) | 9.05 | 6.67 | 3.08 | 2.30 | 1.82 |
Debt / equity (x) | 0.01 | 0.02 | 0.02 | 0.03 | 0.71 |
Asset turnover (x) | 0.55 | 0.57 | 0.56 | 1.32 | 1.31 |
Days sales outstanding (days) | 59 | 26 | 69 | 47 | 82 |
Days inventory outstanding (days) | 509 | 328 | 245 | 167 | 208 |
Days payables outstanding (days) | 35 | 37 | 76 | 54 | 191 |
Cash conversion cycle (days) | 533 | 317 | 238 | 160 | 99 |
Revenue by Region and Revenue by Region (%)
| Region | FY2025 | FY2026 |
|---|---|---|
ANZ revenue (AUD Mn) | 14.1 | 19.4 |
International revenue (AUD Mn) | 8.9 | 6.3 |
of which China CBEC (AUD Mn) | — | 4.9 |
of which Vietnam (AUD Mn) | — | 1.4 |
Group revenue (AUD Mn) | 22.9 | 25.7 |
ANZ share of revenue (%) | 61.6 | 75.5 |
Region growth (%) | FY2026 | — |
ANZ revenue growth (%) | 37.9 | — |
International revenue growth (%) | -29.3 | — |
Valuation Snapshot
| Metric | Value |
|---|---|
IPO price (9 Dec 2019) | A$2.60 |
First-day close | A$3.24 |
Latest price (12 Oct 2026) | A$0.080 |
Change since IPO (%) | -96.9 (unadjusted for rights issues) |
1-year change (%) | -46.9 (to Jul 2026, StockAnalysis) |
52-week range | A$0.068 – A$0.200 |
Beta | 0.84 (StockAnalysis) |
Average daily volume (3 months) | ~46,100 shares (Investing.com) |
Price reference (AUD) | Dec2019 |
Share price at event (AUD) | 2.60 |
Valuation Multiples
| Multiple | Nuchev | Bubs Australia |
|---|---|---|
Market capitalisation (local M) | 12.5 | 76.9 |
Enterprise value (AUD Mn) | 14.6 | — |
EV/Sales or P/S (x) | 0.57 | 0.69 |
P/B (x) | 2.1 | — |
Analyst Ratings & Targets
| Broker / source | Rating | Target (AUD) | Date |
|---|---|---|---|
Wilsons | Not stated | 0.19 (cut 22%) | — |
TipRanks aggregated | Hold | 0.14 | Circa mid-2025 |
Current consensus | — | — | Simply Wall St indicates coverage by 1 analyst |
“—” = not publicly disclosed.
Capital Markets
| Item | Detail |
|---|---|
Dividend history | No dividends ever paid |
Dividend policy | None stated; accumulated losses preclude near-term dividends |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt facilities | A$6.0m unsecured working-capital facilities from H&S Group (A$3.5m drawn, A$2.5m available at 30 Jun 2026); the initial A$4m facility priced at BBSW + 10% margin with interest/fees capitalisable |
Debt maturity profile | 100% of drawn borrowings mature 31 Mar 2028; lease liabilities A$0.69m (A$0.21m current) |
Debt maturity (AUD Mn) | FY2027 |
Borrowings maturing (AUD Mn) | 0 |
Lease liabilities current/non-current (AUD Mn) | 0.21 |
Analyst Conclusions
Management guidance
No formal FY27 earnings guidance. Planning assumptions: domestic retail growth; full-year Brauer distribution contribution; progress in international markets; Practitioner rebuild; further facility drawdowns as required. Downside levers identified (discretionary spend, inventory, launch timing, collections, payment sequencing).
Consensus expectations
No publicly available consensus forecasts for FY27 revenue or EBITDA were identified.
Bull case
-
Operating leverage on an already-built platform. Employee and marketing costs (A$11.9m combined in FY26) were built ahead of revenue; a full year of distribution revenue plus Kuci could lift revenue materially above A$25.7m with limited incremental fixed cost, narrowing the A$4.6m adjusted EBITDA loss back toward the FY25 trajectory.
-
Non-dilutive cash catalysts. Successful enforcement of the ~A$1.9m Nouvlait award would nearly double FY26 closing cash, and the consignment structure of Kuci adds revenue without inventory investment.
-
Domestic brand strength. Oli6's 37.9% ANZ growth and tier-one ranging, combined with adjacencies and D2C, provide a defensible core; at ~0.57x EV/Sales, any visible progress toward break-even could re-rate the stock from a micro-cap base.
Bear case
-
Funding gap. Liquidity of ~A$4.6m (cash plus undrawn facilities) against FY26 operating burn of A$6.6m implies further capital will likely be required within 12 months; with a ~A$12.5m market cap, equity issuance would be heavily dilutive, and further related-party debt deepens dependence at a BBSW + 10% cost.
-
Margin structurally lower. Distribution revenue carries lower gross margin; FY26 margin fell 3.7pp and the derived 2H FY26 margin was ~41%, so revenue growth may not translate into gross-profit growth sufficient to cover a A$11m+ operating cost base.
-
Governance and concentration. H&S Group's roles as shareholder, lender, distributor, supplier and Biomera owner, with two board-linked directors and limited independent oversight, create minority-shareholder risk; repeated leadership turnover and a full goodwill write-off on the only acquisition undermine execution credibility.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| ~30 Oct 2026 | FY26 Annual Report (auditor's going-concern note, remuneration report, top 20 holders, segment note) |
| Late Oct 2026 | Q1 FY27 Appendix 4C — first quarter of full distribution model; cash burn and facility drawdown |
| Oct–Nov 2026 | AGM — resolutions, director elections, any capital-structure approvals |
| From Sep 2026 | Nouvlait award enforcement progress in PRC courts |
| FY27 | Kuci sell-through in Chemist Warehouse |
| FY27 | Vietnam new-product registration resumption |
| 31 Dec 2026 | Vesting date for CEO retention rights |
| Late Jan 2027 | Q2 FY27 Appendix 4C |
| Late Feb 2027 | H1 FY27 results — gross margin recovery, adjusted EBITDA trajectory |
| Ongoing | Any equity raise or facility upsizing; H&S ownership changes and option exercises; renewal of H&S Oli6 distribution arrangements following the initial three-year term |
Analyst verdict
Nuchev has achieved something its IPO-era investors would recognise only partially: it has survived the collapse of its original China-led goat-formula thesis and rebuilt a broader, ANZ-centric nutrition and wellness business with A$25.7m of revenue, a credible domestic Oli6 franchise and a widening set of routes to market. The 27.5% revenue CAGR since FY22 is real, and the domestic engine (+37.9% in FY26) demonstrates that the brand and the retail relationships have value.
The problem is conversion. Every incremental initiative since 2023 — the bWellness acquisition, the H&S distribution model, Kuci — has added revenue and complexity, but the company has not yet shown that revenue growth turns into gross profit, let alone EBITDA or cash. FY26 was a step backward on every profitability and liquidity measure: gross margin down 3.7pp, adjusted EBITDA loss up 36%, operating cash burn up 77%, equity nearly halved, and the bWellness goodwill written off in full. The going-concern material uncertainty is not boilerplate here; liquidity of roughly A$4.6m against a A$6.6m annual burn leaves little room for error.
The company's fate is increasingly intertwined with H&S Group, which is simultaneously its most important distributor, brand supplier, lender, major shareholder and board presence. That relationship is the reason Nuchev remains funded, but it also concentrates strategic control and complicates the assessment of whether agreements are optimised for all shareholders.
Our view is that NUC is a high-risk, binary micro-cap. The upside case — operating leverage from a full distribution year, capital-light Kuci revenue and a non-dilutive arbitration recovery — is plausible but unproven. Until Nuchev delivers at least two consecutive quarters of improving gross margin and narrowing cash burn without additional dilution, the balance of evidence favours caution. Key watch items are the Q1 FY27 4C, the AGM, and any capital-management announcements.
End of dossier. All figures in A$ unless stated; FY = year to 30 June. Data current to 12 October 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Compensation |
|---|---|---|---|---|
Nathan Cheong | Chief Executive Officer | CEO since 12 May 2025; Independent NED 11 Sep 2024 – May 2025 | CEO/MD of Melrose Group; CEO of LifeSpace Group; roles at Designs for Health, BioCeuticals and Global Therapeutics; 20+ years in the complementary-medicines industry | FY26 remuneration not available in sources reviewed. Appointment terms: 6-month notice; equity rights vest if employed through 31 Dec 2026 (lapse otherwise), priced off 30-day VWAP before appointment |
Matthew (Matt) Parker | Chief Financial Officer | Interim CFO from 6 Jan 2026; permanent from 1 May 2026 | 25+ years in finance; CFO and Company Secretary roles at ASX-listed Paragon Care, GALE Pacific and Phoslock Environmental Technologies | — |
Mick (Michael) Myers | Former CFO (from 30 May 2022), interim CEO (15 Dec 2023), CEO (1 Jul 2024 – 12 May 2025), then COO and CFO | Departure date not publicly confirmed; interim CFO appointment in Dec 2025 implies exit by late 2025 | — | Total compensation A$679.5k with ~59.7% salary in his CEO year (Simply Wall St; fiscal year of measurement not specified) |
Board of Directors
| Director | Role | Appointed | Independence (analyst view) | Background | Committees |
|---|---|---|---|---|---|
Ben Dingle | Chair | Founder (2013); Chair by May 2024 | Not independent (founder, former CEO) | Founder and former CEO of Nuchev; co-founder of Synlait Milk (NZ) | — |
Craig Silbery | Non-Executive Director | 16 Oct 2023 | Not independent (substantial shareholder; 40% indirect owner of related-party Biomera via CS Mana Pty Ltd) | Substantial holder (5.01%, 7,326,931 shares at notice); took shortfall shares in 2024 entitlement offer | — |
Meng (Leo) Zhang | Non-Executive Director | 26 May 2025 | Not independent (executive roles within H&S Group, substantial shareholder, lender and distribution counterparty) | 10+ years in cross-border brand management, trade and governance; led H&S Global Brand Center (CBEC and SE Asia brand building) | — |
Elizabeth (Liz) Smith | Non-Executive Director | Jul 2024 | Independent | Former Corporate Finance Partner at William Buck and Grant Thornton; audit at Ernst & Young; NED of Pureprofile (ASX: PPL), BikeExchange (ASX: BEX), DGL Group (ASX: DGL) | Chair, Risk Committee; member, People & Culture Committee |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
22 Sep 2023 | CEO Greg Kerr resignation announced | Followed completion of H&S deal |
15 Dec 2023 | Mick Myers interim CEO (and CFO) | Search for permanent CEO |
1 Jul 2024 | Myers permanent CEO | Post-bWellness |
12 May 2025 | Nathan Cheong CEO; Myers to COO/CFO | Board described as natural transition; third CEO in ~3 years |
6 Jan 2026 | Matt Parker interim CFO | Myers no longer CFO |
1 May 2026 | Parker permanent CFO | — |
Major Shareholders
| Holder | Stake | Source / date | Notes |
|---|---|---|---|
Craig Silbery | 5.01% (7,326,931 shares) at time of notice | Substantial holder notice (date c.2024–2025) | Also director |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs Nuchev | Scale (latest verified) |
|---|---|---|---|
Goat / premium infant formula | Bubs Australia (ASX: BUB) | Direct goat-milk IMF rival (Bubs goat formula, CapraKids); larger, US-led growth; also active in China CBEC goat IMF and Vietnam | FY26 revenue A$111.9m; underlying EBITDA A$5.3m; reported EBITDA -A$1.8m |
Infant formula (A2 protein) | The a2 Milk Company (ASX: A2M / NZX: ATM) | Category leader in Australian/China premium IMF; scale, SAMR registrations, owned manufacturing | FY26 revenue NZ$1,974.9m; underlying EBITDA NZ$307.6m (15.6% margin); reported EBITDA NZ$284.4m |
Goat infant formula | Ausnutria (Kabrita brand) | Global goat-formula leader with China presence | — |
Goat infant formula | Dairy Goat Co-operative (NZ) | Goat formula manufacturer/brand owner | — |
Infant formula | Bellamy's Organic (China Mengniu) | Premium organic IMF in Australian grocery/pharmacy | — |
Infant formula | Nestlé (NAN), Danone (Aptamil/Karicare), Abbott | Multinational incumbents dominating supermarket and pharmacy shelf | — |
Practitioner complementary medicines | Metagenics, BioCeuticals (Blackmores Group/Kirin), MediHerb, Designs for Health | Practitioner-channel incumbents with far larger field forces | — |
Retail vitamins & supplements | Blackmores (Kirin), Swisse (H&H Group), Nature's Way, Herbs of Gold | Mass-market VMS brands competing for pharmacy shelf | — |
Skincare (Skin Physics) | Numerous pharmacy cosmeceutical brands | Fragmented | — |
Weight management (Rapid Loss) | Optislim, others | Fragmented | — |
Women's health probiotics (Kuci) | Brands of large VMS players | Early-stage category for Nuchev | — |
Peer Comparison FY2026
| Metric | Nuchev (FY26) | Bubs Australia (FY26) | a2 Milk (FY26) |
|---|---|---|---|
Revenue (local currency, M) | 25.7 (A$) | 111.9 (A$) | 1974.9 (NZ$) |
Revenue growth (%) | 12.0 | 9.2 | 12.4 |
Gross margin (%) | 43.6 | — | 47.7 |
EBITDA margin, underlying/adjusted (%) | -17.9 | 4.7 | 15.6 |
EBITDA margin, reported (%) | — | -1.6 | 14.4 |
Recent Developments
--



